Clostridioides difficile is a ubiquitous, diarrheagenic pathogen often associated with healthcare-acquired infections that can cause a range of symptoms from mild, selflimiting disease to toxic megacolon and death. Since the early 2000s, a large proportion of C. difficile cases have been attributed to the ribotype 027 (RT027) lineage, which is associated with sequence type 1 (ST1) in the C. difficile multilocus sequence typing (MLST) scheme. The spread of ST1 has been attributed, in part, to resistance to fluoroquinolones used to treat un-related infections, which creates conditions ideal for C. difficile colonization and proliferation. In this study, we analyzed 27 isolates from a healthcare network in northern Arizona, USA, and 1,352 public ST1 genomes to place locally-sampled isolates into a global context. Core genome, single nucleotide polymorphism (SNP) analysis demonstrated that at least 6 separate introductions of ST1 were observed in healthcare facilities in northern Arizona over an 18-month sampling period. A reconstruction of transmission networks identified potential nosocomial transmission of isolates following two of these introductions, which were only identified via whole genome sequence analysis. Antibiotic resistance Page 2 of 34 heterogeneity was observed among ST1 genomes, including variability in resistance profiles among locally sampled ST1 isolates. To investigate why ST1 genomes are so common globally, we compared all high-quality C. difficile genomes and identified that ST1 genomes have gained and lost a number of genomic regions compared to all other C. difficile genomes; analyses of other toxigenic C. difficile sequence types demonstrates that this loss may be anomalous and could be related to niche specialization. These results suggest that a combination of antimicrobial resistance and gain and loss of specific genes may explain the prominent association of this sequence type with C. difficile infection cases worldwide. The degree of genetic variability in ST1 suggests that classifying all ST1 genomes into a quinolone-resistant hypervirulent clone category may not be appropriate. Whole genome sequencing of clinical C. difficile isolates provides a high-resolution surveillance strategy for monitoring persistence and transmission of C. difficile and for assessing the performance of infection prevention and control strategies.
Introduction
Clostridioides difficile (1) is one of the most commonly observed diarrheal pathogens in hospital settings. C. difficile infection (CDI) can range in severity from asymptomatic carriage or mild disease to toxic megacolon and death. The recent rise in the frequency in CDI has been attributed, in part, to the spread of fluoroquinoloneresistant strains of ribotype (RT) 027. Strain CD196, the earliest identified RT027 isolate (2) , was isolated in France in 1985 (3) . RT027 was linked to CDI outbreaks in North America and Europe in the 2000s (4) (5) (6) (7) (8) and has spread around the world (9) .
Although a decrease in the prevalence of RT027 has been reported in some regions (10) , the RT027 lineage continues to be routinely isolated from clinical samples (11) (12) (13) (14) (15) (16) . Although the mechanisms behind the success of the RT027 lineage are not fully understood, the increase of CDI cases caused by RT027 in the 2000s has been linked to strains with fluoroquinolone resistance (4, 9) . It has also been suggested that the RT027 lineage can displace endemic strains (17) and, more recently, Collins and colleagues (18) associated an increased ability to metabolize trehalose with epidemic ribotypes (RT027 as well as RT078) suggesting this trait along with the increased addition of trehalose to foods contributed to the success of RT027.
Many typing methods have been used to characterize C. difficile isolated from clinical settings. Ribotyping, a method that relies on differential amplification length profiles of ribosomal intergenic spacer regions, has been one of the most widely used procedures (19, 20) . Multilocus sequence typing (MLST) has also been a commonly applied approach for characterizing C. difficile diversity and is more appropriate than ribotyping for examining evolutionary history and relatedness (21) . RT027 is associated with sequence type (ST) 1 in the C. difficile MLST scheme (22) . Additional ribotypes associated with ST1 include RT016, RT036, and RT176 (21) . Ribotype 016 has been isolated from stool samples associated with CDI in England (23) and RT176 has been associated with CDI in Poland (24) and the Czech Republic (25) . Ribotyping and MLST are increasingly being replaced by comparative genomic methods that rely on whole genome sequence (WGS) data. Ribotyping results, MLST profiles, and comparisons utilizing the entire genome are not always congruent (20) ; WGS provides the highest resolution for comparative genomics and should be the focus of comparative studies moving forward. The primary focus of this study is a comparison of ST1, which forms a monophyletic clade (see Results) and includes many virulent isolates collected from human clinical samples.
Multiple studies have investigated C. difficile with comparative genomics, with several studies focused on disease caused by ST1 (RT027). In one comparative study of three C. difficile genomes (2), the authors identified several genomic regions potentially associated with increased virulence of RT027. Since that time, genomic sequences from many additional strains have become available. A large comparative genomics study of C. difficile isolates collected from patients with diarrhea in hospital systems in the U.K. over a 4-year period indicated that the ST1 lineage was prevalent (17% of samples) (26) . Another study that included 1,290 isolates from patients with CDI in the same area found that 35% of the isolates were ST1 (27) . He and colleagues (9) investigated the global phylogeny and spread of RT027 (ST1) with whole genome SNP analysis and identified two epidemic lineages, both of which contained a mutation conferring fluoroquinolone resistance. As these studies demonstrate, ST1 isolates have been frequently identified from clinical samples; other studies have indicated that ST1 isolates are less commonly associated with other environments (e.g. soils, dogs, etc.) (28) (29) (30) (31) . Although not conclusive, together these studies suggest that ST1 isolates may preferentially colonize the human gut over other environments.
One of the primary concerns about CDI is emerging antimicrobial resistance (AMR). Antibiotic-associated pseudomembranous colitis has been associated with C. difficile since the late 1970s (32) (33) (34) . Resistance to a variety of antimicrobials has been associated with C. difficile isolates, many of which are multi-drug resistant ((35, 36) and references therein). Antimicrobial resistance in C. difficile may vary between lineages or by region due to differing antimicrobial use and can impact CDI in regards to infection, recurrence, and disease outcome (35, 36) . As mentioned previously, fluoroquinolone resistance has been associated with many ST1 (RT027) strains, and this resistance likely contributed, at least partially, to the increase in CDI cases attributed to ST1 during the 2000s as fluoroquinolone use increased during the 1990s and early 2000s (4, 9, (37) (38) (39) . Fluoroquinolone resistance in ST1 strains has been associated with mutations in the gyrA and gyrB genes (40, 41) . Suggested clinical guidelines for treating CDI currently include treatment with vancomycin, fidaxomicin, and metronidazole (42) . Although reduced susceptibility to these compounds has been reported, resistance in C. difficile has had limited impact on the efficacy of these drugs in the clinic thus far (42, 43) . Understanding AMR in C. difficile may yield insights into the prevalence of CDI caused by certain lineages and provide information regarding best practices for prescribing antibiotics.
In this study, we examined 27 ST1 genomes generated as part of a surveillance project across two healthcare facilities in northern Arizona, USA during 2016 and 2017 and publicly available C. difficile genomes. Comparisons were conducted to: 1) characterize northern Arizona ST1 isolates in the context of a worldwide set of genomes; 2) evaluate potential transmission networks within Arizona healthcare facilities; 3) use genomics characterize antimicrobial resistance profiles and to identify potential mechanisms that have allowed for the widespread presence and dominance of the ST1 lineage across hospitals worldwide; and 4) better understand the pangenomics and phylogenomics of the species in general. We also developed an in silico ribotyping method for relating whole genome sequence data and ribotyping information.
Methods
Genome download and sequence typing. All available C. difficile genome assemblies (n=1,092) were downloaded from GenBank on November 30, 2017. For quality control purposes, statistics were gathered for each genome for number of contigs, number of ambiguous nucleotides (non A,T,G,C), and total genome assembly size. Additionally, all raw sequencing data (paired-end Illumina data only) associated with C. difficile available from the Sequence Read Archive (SRA) on September 1, 2017 were downloaded (sratoolkit fastq-dump). For isolates represented by multiple SRA runs, the runs were combined and labeled with the BioSample accession. Data were discarded if the read length was less than 75 bp. The multilocus sequence type (ST) of samples represented by raw read data was determined with stringMLST v0.5 (default settings) (44) . Samples typed as ST1 were assembled with SPAdes v3.10.0 (--careful --cov-cutoff auto -k auto) (45) . These genome assemblies were combined with GenBank assemblies for downstream analyses; in some cases, these reads represent duplicates of GenBank assemblies, but were treated independently in this study due to difficulties with association. Any GenBank assembly or assembly generated with SPAdes that contained greater than 1,500 contigs, greater than 10 ambiguous nucleotides, an anomalous genome assembly size (final data set: <3,600,277 or >4,698,454bp), or anomalous GC content (final data set: <28.07 or >29.74%) was removed from the data set. In addition, all pairwise MASH (v2.0, default sketch size) (46) distances were calculated for all genome assemblies in order to find genomes annotated as C. difficile but belonging to different species. Genomes with an average pairwise MASH distance >0.03, which corresponds to <0.97 average nucleotide identity (a conservative cutoff value), were removed from the dataset (average MASH distances for remaining genomes were less than 0.02). The ST was determined for all assemblies passing quality control metrics with a custom script (https://gist.github.com/jasonsahl/2eedc0ea93f90097890879e56b0c3fa3) that utilizes BLAST and the PubMLST database (https://pubmlst.org/) for C. difficile (22) . For ST1 genomes, if the ST of the assembly did not match the ST predicted by stringMLST, the assembly was removed from the dataset. A total of 1,850 genome assemblies from NCBI data (609 Genbank assemblies and 1,241 in-house assemblies from the SRA identified as ST1) were included in this study (Table S1 ). Additionally, publicly available raw sequencing reads representing non-ST1 isolates (n=3,402) were included in the in silico ribotyping analyses (see below). Terriquez and were stored at -80°C until processing. Isolation of C. difficile from stool samples was performed as outlined in Edwards et al. (47) with the following modifications; one 10 µL loopful of partially thawed stool was re-suspended in 500 µL of sterile 1x PBS in aerobic conditions. The suspension was immediately transferred to a vinyl Type C anaerobic chamber (Coy Laboratory Products, Grass Lakes, MI, USA), where 100 µL was plated onto pre-reduced taurocholate-cefotoxin-cyloserinefructose agar (TCCFA) and incubated at 36°C for 24-48 hours. Suspected C. difficile were sub-cultured onto pre-reduced brain heart infusion agar supplemented with 0.03% L-cysteine (BHIS) and incubated anaerobically at 36°C for 24 hours. Once isolation of suspected Clostridioides/Clostridium spp. was achieved, a lawn was created (also on BHIS) and incubated anaerobically at 36°C for an additional 24 hours.
Genomic DNA was extracted from each isolate, C. difficile species identification was confirmed via TaqMan® PCR, and all C. difficile positive extractions were processed for downstream WGS as described previously (31) . Based on this methodology, a total of 27 ST1 isolates were identified from hospitals in northern Arizona between March 2016 and September 2017 ( Table 1) . DNA was sequenced on the Illumina MiSeq platform and all genomes were assembled with SPAdes v3.10.0. The average per contig depth of coverage was calculated with genomeCoverageBed (48) from BWA-MEM v0.7.7 alignments (49) . Additionally, 200 bases of each contig was aligned against the GenBank (50) nt database with BLASTN (51) and the identity of the top hit was tabulated. If the alignment was from a known contaminant or from a different species sequenced on the same run, the contig was manually removed from the assembly.
Simulated reads. Genome assemblies have been shown to provide more noise when inferring the phylogenetic structure of a species compared to raw read data (52) . For all publicly available genome assemblies downloaded from GenBank and passing filters, simulated reads were generated with ART (53) version MountRainier with the following command: art_illumina -ss MSv3 -l 250 -f 75 -m 300 -s 30. Simulated reads instead of genome assemblies were used for SNP discovery and phylogenetics for ST1 genomes.
Phylogenetic analyses. To generate a preliminary phylogeny, genome assemblies (n=1,877) were aligned against the finished genome of C. difficile CD630 (GCA_000009205.1) with NUCmer (MUMmer v3.23) (54), and SNPs were called in conjunction with NASP v1.1.2 (52) . A maximum likelihood phylogeny was inferred on an alignment of 85,331 concatenated SNPs (Table S2 ) called from a core genome alignment of 1,860,526 positions with IQ-TREE v1.6.1 (55) using the best-fit model (GTR+F+ASC+R5) identified by ModelFinder (56) SNPs were called from the alignments with the Unified Genotyper method in GATK v3.3-0 (61, 62) . Positions in duplicated regions of the reference genome (identified with NUCmer), positions with less than 10X coverage, and positions with a mixture of alleles (<0.9 single allele) were removed from the analyses. SNP positions with calls in at least 90% of the analyzed genomes were concatenated (n=4,283 SNPs, Table   S3 ). A maximum likelihood tree was inferred with IQ-TREE v1.6.1 (best-fit model TVMe+ASC+R2). The tree was rooted with the ST1 genome ERR030325 based upon previous phylogenetic analysis. Phangorn was used to calculate the consistency index and retention index as described above. to the BEAST xml file. A "path and stepping stone" sampling marginal-likelihood estimator was used in order to determine the best-fitting clock and demographic model combinations (68) . The log marginal likelihood was used to assess the statistical fits of different clock and demographic model combinations (Table S5 ). Four independent chains of one billion iterations were run for the best clock and demographic model combination. Convergence among the four chains was confirmed in the program Tracer version 1.6.0 (http://tree.bio.ed.ac.uk/software/tracer/). for easily mapping the number of SNP differences between isolates). Epidemiological data were collected from healthcare facilities but, in some cases, information was incomplete.
Root

C. difficile transmission and persistence analysis.
In silico predicted antimicrobial resistance profiling. Proteins (n=2,177) from the comprehensive antimicrobial resistance database (CARD) (74) were downloaded on December 18th, 2017. Protein sequences were aligned against all ST1 genomes with the TBLASTN option in LS-BSR. Any peptide with a BSR (75) value > 0.9, which is equivalent to 90% ID over 100% of the peptide length (76) , was investigated further.
Several mutations associated with fluoroquinolone resistance have been published in the literature (36, 40, 41, 77) . For GyrA (CD630DERM_00060) and GyrB (CD630DERM_00050), predicted protein sequences were extracted for all genome assemblies from TBLASTN alignments and then aligned with MUSCLE (73) . The states of mutations associated with fluoroquinolone resistance were manually investigated. (ST) if the BSR value for the CDS was greater than 0.8 for greater than 95% of targetgroup genomes and the BSR value was greater than 0.4 in less than 5% of genomes of the non-target group.
Gene regions have been identified in ST1 genomes that have been linked to virulence (2) ( Table S6 ). Because these regions were discovered utilizing a small number of genomes, we screened the peptide sequences from these regions against all genomes with LS-BSR using the TBLASTN alignment option. Additionally, genome assemblies were screened for genomic features associated with trehalose metabolism (18) (Table S6 ). For TreR (CBA65726.1), sequences were pulled out of all genome assemblies from TBLASTN alignments and then aligned with MUSCLE (73) . The state of a mutation associated with increased trehalose metabolism was manually investigated. Genome assemblies were also screened for proteins encoded by a four gene region associated with increased trehalose metabolism (FN665653. 
Results
C. difficile ST1 isolates from two healthcare facilities in northern Arizona were examined to understand the ST1 isolates present in northern Arizona in the context of a global collection of C. difficile, to identify potential transmission events and to characterize AMR and the core/pan-genome within the isolates.
Phylogenetic diversity of C. difficile. A maximum likelihood phylogeny ( Figure 1) was inferred on a concatenation of 85,331 SNPs (Table S2) An additional phylogenetic analysis was conducted for only ST1 genomes (n=1,379). A maximum likelihood phylogeny ( Figure 2 ) was inferred on a concatenation of 4,283 SNPs (Table S3 ). The consistency index (excluding parsimony uninformative SNPs) is 0.87, and the retention index of this phylogeny is 0.98. The
GyrA Thr82Ile mutation conferring fluoroquinolone resistance is conserved in two lineages labeled FQR1 and FQR2 (9) . Isolates from two northern Arizona hospitals genome, this rate correlates to less than one SNP per genome per year. This SNP accumulation rate is slightly lower than a previous estimate for ST1 (9) , as well as within host rates for C. difficile isolates from clinical samples (26, 82) . The estimated divergence time for the ST1 clade genomes included in our analysis is 40.06 years ago (95% HPD interval between 32.14 to 49.54 years).
Analysis of C. difficile transmission and persistence.
Core genome SNP phylogenies for isolates collected from healthcare facilities in this study were paired with patient epidemiological data to provide insight into C. difficile prevalence, acquisition, and transmission within and between the two facilities (labeled A and B) ( Figure 3 ). The estimated evolutionary rate within C. difficile ST1 genomes suggests that very few SNPs separate isolates involved in recent transmission events, which has been observed previously (26) . Patient location information reveals that patients with CDI-associated diarrhea were frequently moved to multiple locations within a facility and once between facilities. Northern Arizona isolates within clade 1 are closely related, and isolates within clade 6 are also differentiated by very few SNPs ( Figure   2 ). Isolates separated by 0 SNPs are observed at the same healthcare facility at multiple timepoints (e.g. Clade 6: HS-FS-000188, HS-FS-000020, HS-FS-000251 in Figure 3 ) and across both healthcare facilities (e.g. Clade 1 HS-FS-000016, HS-FS-000023; Clade 6: HS-FS-000024, HS-FS-000031, HS-FS-000057 in Figure 3 ).
Isolates HS-FS-000057 and HS-FS-000043 are separated by 1 SNP and the two patients from which these isolates were sampled resided at the same skilled nursing facility, which is a third and separate entity from the two facilities at which samples were collected in this study. Thus, our analysis identifies potential transmission of C.
difficile within the healthcare network. Some isolates (e.g. HS-FS-000148 in clade 1) are more distantly related to other sampled isolates, which could indicate infections acquired from community or environmental reservoirs. C. difficile within clades 1 and 6 appear to be prevalent in northern Arizona (though sampling in this study is limited to clinical specimens from two facilities) and are perhaps circulating within healthcare facilities.
On two occasions multiple isolates were sampled from the same patient. Isolates HS-FS-00084 and HS-FS-000103 (clade 1, Figure 2) were collected from the same patient 16 days apart; isolates HS-FS-000264 and HS-FS-000287 (clade 5, Figure 1) were collected from a different patient one month apart. In both cases, the isolates sampled from the same patient were separated by zero SNPs, indicating persistent infections or re-infections from the same source rather than new infections with a new genotype.
In silico predicted AMR profiles in ST1 genomes. To understand AMR among northern Arizona isolates as well as ST1 in general, all ST1 genomes were screened against 2,177 proteins in the CARD database with LS-BSR ( (Table 1) .
DfrF has been associated with resistance to trimethoprim in Enterococcus faecalis (95) and Streptococcus pyogenes (96) . Proteins encoded by the vanG operon associated with vancomycin resistance in E. faecalis (MIC 16 µg/ml) (97) were identified for two ST1 genomes (BSR values ranging from 0.92 to 1), including one isolate from northern Arizona (HS-FS-000151). These genes were identified in addition to the vanG-like gene cluster identified in C. difficile (94) , which is highly conserved among C. difficile genomes.
In addition to gene presence/absence, several SNP mutations have been described that confer resistance to quinolones (36, 40, 41, 77) . A comparison of SNP calls across all C. difficile genomes at those positions demonstrated that >95% of ST1 genomes contained the GyrA Thr82Ile mutation that confers quinolone resistance, whereas only ~12% of non-ST1 C. difficile genomes screened here have this mutation.
Interestingly, genomic data for 5 of the 27 isolates from CDI cases at northern Arizona facilities indicate these isolates do not have the GyrA Thr82Ile mutation conferring quinolone resistance (clades 2-5 in Figure 2 ). Additional mutations in GyrA and GyrB associated with quinolone resistance were not broadly conserved in ST1 genomes (Table S9 ). These results suggest that AMR varies among ST1 isolates (and among northern Arizona isolates from the same hospital) and that factors in addition to AMR likely contribute to the success of ST1 in the human/hospital environment.
Antimicrobial Resistance Testing. Four northern Arizona isolates (this study) with
varied in silico predicted AMR profiles (Table 1) were screened for antimicrobial resistance using Etests (Table S10 ). These four isolates (HS-FS-000082, HS-FS-000127, HS-FS-000151, HS-FS-000264) were chosen to represent the diversity of in silico predicted AMR profiles among northern Arizona isolates ( operon in E. faecalis (described above); however, this region did not appear to confer increased resistance to vancomycin in the tested isolate.
Pan-genome composition of ST1 genomes. LS-BSR analyses were performed to understand the size and extent of the ST1 core and pan-genome, to identify CDSs that may contribute to the association of ST1 with the hospital environment, and to evaluate potentially unique features of northern Arizona isolates. The strict core genome (CDSs conserved in all genomes using the LS-BSR method) of 1,379 C.
difficile ST1 genome assemblies was determined by LS-BSR to be 1,991 CDSs (Table   S11 ), which corresponds to approximately 55% of the total CDSs in the ST1 genome CD196. The analyzed ST1 genomes spanned a wide range of assembly quality, which could result in underestimation of the core genome size. However, evaluating CDSs that are highly conserved among ST1 genomes could provide insight into why the lineage is so successful in addition to fluoroquinolone resistance. BSR values were used to identify CDSs that have been gained or lost in ST1 genomes. CDSs (n=44)
were identified as highly conserved among ST1 genomes and largely absent from non-ST1 genomes, whereas 14 CDSs were identified as being lost from ST1 genomes (highly conserved among non-ST1 genomes and largely absent from ST1 genomes, see methods for criteria) (Table S12 ). CDSs identified as highly conserved in ST1 include some genomic regions previously identified as unique to RT027 isolates in a comparison of three genomes (2) . For example, CDSs associated with the insertion of a catalytically more efficient thyA gene that disrupts the thyX gene in previously studied RT027 isolates (83) are highly conserved in the ST1 genomes analyzed here; these CDSs were upregulated by an ST1/RT027 isolate during the early stage of an infection in a monoxenic mouse model (84) . Additional CDSs highly conserved in ST1 genomes are annotated as transposases or have unknown functions (Table S12 ).
Binary toxin genes (cdtA and cdtB) are highly conserved within ST1 and largely absent from many other STs but did not meet the threshold defined here to be included as gained/lost CDSs.
To understand if the phenomenon of gene acquisition/loss is common across all Although ST11 (RT078) genomes were excluded from the initial round of this analysis due to filtering genome assemblies by MASH distance, CDSs identified as highly conserved or generally lost within ST1 were compared to ST11 lineage genomes (n=15). The ST11 lineage has been associated with severe disease and has been commonly isolated from clinical samples as well as agricultural, animal, and retail meat samples (81, (85) (86) (87) (88) (89) (90) . Several CDSs identified as highly conserved within ST1
were also conserved in ST11 genomes (Table S12 ). These CDSs include a DNAbinding regulator, a histidine kinase, and an RNA polymerase sigma factor. Some
CDSs identified as generally lost within ST1 are conserved within ST11 (e.g. a TetR/AcrR family transcriptional regulator).
Although LS-BSR analysis indicates that over half of the predicted CDSs present in the genome for strain CD196 are part of the strict core genome for ST1 isolates, some of the CDSs present in this genome (and others within ST1) are differentially conserved throughout the ST1 lineage. Some CDSs are clade-specific or have been lost in particular clades of ST1 ( Figure S1 ). 5,937 CDSs were identified in the accessory genome for ST1, and 1,049 CDSs were identified as unique to one genome.
This variation in genomic content within the ST1 lineage suggests that different clades/isolates within ST1 will vary phenotypically, which could impact AMR, transmission, and virulence. For example, Stone and colleagues (submitted and in review) found variable toxin production among three ST1 strains using a transepithelial electrical resistance (TEER) assay. To understand the genetic composition of northern Arizona isolates, LS-BSR was used to identify any unique CDSs within clades 1-6 in Figure 2 compared to other ST1 isolates, but no CDSs were found to be unique to any of these clades. However, isolates HS-FS-000082 and HS-FS-000151, both within clade 1, each contained a CDS not identified in any other ST1 genome (HS-FS-000082 -ABC transporter permease, HS-FS-000151 -site-specific integrase).
A set of 52 peptide sequences (2) previously associated with differential conservation in ST1 genomes (Table S6) were screened against all genomes with LS-BSR. The results indicate that several features associated with an epidemic ST1 strain are also present in non-ST1 genomes (Table S13) (Table S13) , including three ST1 genome assemblies (ERR026353, ERR030384, ERR251831; in-house assemblies from publicly available sequencing read data). The four protein sequences were not identified for any of the 27 northern Arizona isolates sequenced here.
In silico ribotyping. The gold standard for C. difficile genotyping has been ribotyping, wherein RT027 isolates are primarily associated with ST1 (22) . Here we have focused on ST1, which forms a monophyletic clade within a whole genome SNP phylogeny ( Figure 1 ). However, there appears to be a disconnect in the literature between researchers using ribotyping and those using either MLST or WGS approaches. To relate northern Arizona isolates to published C. difficile PCR ribotypes without the need for performing PCR ribotyping in the laboratory, we explored the potential to extract ribotyping profiles from sequence data. To examine the utility of an in silico ribotyping approach, raw sequencing reads from the SRA with associated MLST profiles were aligned against amplicons predicted by probing standard ribotyping primers against three finished ST1 genomes, and hits were identified from samples with even read mapping across all amplicons (see methods). An analysis of different thresholds for variable read mapping demonstrated that 20% of the maximum read counts was an appropriate threshold for calling ribotype amplicons (Table S14 ). Of the 4,670 genomes screened, 1,268 of them were sequence typed as ST1 using stringMLST, and 1,253 of these ST1 genomes were identified as RT027 based on in silico ribotype profiles (Table S15 ). The in silico ribotyping method correctly identified ~99% of ST1 genomes based on their ribotype profiles. Only 17 of 3,402 non-ST1 genomes were identified as ST1. It is assumed here that all ST1 genomes analyzed are RT027 and all non-ST1 genomes are not RT027. ST1 also includes RT016, 036
and 176, but predominantly RT027 isolates have been associated with ST1. All 27
northern Arizona isolates were in silico ribotyped as RT027 and sequence typed as ST1 (in silico) according to the MLST scheme for C. difficile.
PCR ribotyping was performed on 10 C. difficile isolates with various sequence types for comparison to in silico results ( Figure S2 ). Two ST1 isolates presented similar PCR ribotyping profiles, and PCR ribotyping profiles for these two ST1 isolates were comparable to in silico ribotyping results, though not exact matches. The in silico profile included seven bands; one ST1 isolate presented analogs to all seven bands plus one larger band whereas the other ST1 isolate presented six analogous bands plus one larger band (Table S16 ). Variation between ribotyping profiles predicted from four RT027 genome assemblies and actual ribotyping profiles has been reported previously (100) . Non-ST1 isolates produced dissimilar PCR ribotyping profiles to ST1 isolates, and very few non-ST1 isolates were identified as ST1 by the in silico ribotyping method. The in silico ribotyping method described here could potentially provide a means to connect ribotyping information from past studies to the expanding whole genome sequence data available for C. difficile isolates, though the method requires further testing and validation.
Discussion
C. difficile ST1 is a successful worldwide lineage that appears to be especially adapted to the human gut and healthcare environments. The rise of C. difficile in hospitals globally has been attributed, at least partially, to the emergence and proliferation of ST1 (RT027) (101) . In this study, we sequenced 27 ST1 isolates is a distinct lineage that includes only isolates from northern Arizona facilities.
Interestingly, two isolates collected from food samples in Arizona as part of previous studies (9, 81) are closely related to some of the clinical isolates sequenced in this study (clade 1 in Figure 2 ). C. difficile within clades 1 and 6 seem to be prevalent ST1 genotypes circulating within northern Arizona.
Whole genome sequencing provides a high-resolution method for differentiating bacterial isolates and offers insight into how pathogens persist and are transmitted within healthcare networks. Several studies, including this one, have indicated that the SNP accumulation rate in C. difficile is approximately one SNP per genome per year (26, 82) ; however, SNP accumulation rates can be complicated for bacteria with a spore stage in their life cycle (102) . Bayesian analysis suggests that the divergence time for the ST1 lineage is approximately 40 years ago (95% HPD interval between 32.09 to 49.46 years), which is consistent with the identification of the first ST1/RT027 isolate in 1985 (2, 3) . He and colleagues (2013) analyzed a dataset of ST1 genomes and described two epidemic lineages, both of which acquired the GyrA Thr82Ile mutation conferring quinolone resistance; the time of emergence for these two ST1
lineages was estimated to be in the early 1990s. The SNP accumulation rate within C.
difficile must be considered when attempting to track isolates on an epidemiological time scale (103) and cases linked by recent transmission will likely be separated by very few SNPs (26) . The genomic variation among northern Arizona isolates suggests that although some CDI cases from which these isolates were collected may potentially be the result of transmission within healthcare facilities, other cases are seemingly unrelated. We observed that closely related isolates, based on WGS analysis, were sampled in patients at multiple facilities and over multiple time points.
In two instances, whole genome sequencing showed that the same genotype persisted in a patient rather than the patient being infected with a different genotype.
Since patients with CDI are moved between facilities and similar C. difficile genotypes are detected at different facilities, infection prevention strategies must be implemented across the entire healthcare network to be most effective. Putatively unrelated cases may be the result of particular ST1 genotypes circulating in northern Arizona reservoirs and emerging as CDI cases due to antibiotic use or other factors. Importantly, monitoring transmission and persistence of these ST1 isolates with sub-genomic methods, such as ribotyping or MLST, would not have been possible due to a lack of resolution provided by these methods. Incorporating whole genome sequencing and comparative genomics into the healthcare network surveillance program enabled more effective monitoring, which can hopefully improve patient health in the future.
AMR varies within C. difficile (36) and AMR markers detected in genomes for ST1
isolates sampled in this study indicated that in silico predicted AMR profiles for these isolates are also variable. Resistance to fluoroquinolones within C. difficile ST1 has been the focus of many studies (4, 9, (37) (38) (39) and approximately 95% of the ST1 genomes compared in this study have the missense mutation in the gyrA gene ( Figure   2 , Table S9 ) linked to resistance to some fluoroquinolones. The use of quinolones to treat un-related infections may select for ST1, supporting the proliferation of clinical CDI caused by this sequence type. Interestingly, the GyrA Thr82Ile mutation and other mutations known to confer quinolone resistance were absent in five of the 27 ST1
isolates collected in this study. These five isolates account for four introductions of the ST1 lineage into the healthcare network in this region (clades 2-5 in Figure 2 ); one facility within the healthcare network implemented a program to restrict fluoroquinolone use in 2017, which may reduce selection for the GyrA Thr82Ile genotype. AMR screening of northern Arizona isolates with varying in silico predicted AMR profiles (Table S10 ) indicated that all isolates were resistant to ciprofloxacin; resistance to ciprofloxacin is common among C. difficile (36) . Resistance to tetracycline was indicated for one northern Arizona isolate for which a tetM gene was identified in the genome. Use of tetracyclines has not been frequently associated with CDI (104), but a recent report has associated tetracycline resistance to RT078 (105) .
No strains were fully resistant to vancomycin, which is a recommended treatment option for CDI (42) , despite the presence of CDSs associated with vancomycin resistance being detected in one tested genome. Continued screening of C. difficile antimicrobial resistance is important to monitor AMR variability and provide insight for updating treatment guidelines.
Although AMR plays an important role in C. difficile epidemiology, other factors, in addition to quinolone resistance, likely contribute to the prevalence of CDI attributed to ST1. For example, the GyrA Thr82Ile mutation is also highly conserved in ST63 (RT053) genomes, although this ST is not as successful as ST1 based on reported genotype frequencies from hospital isolation (11, 13, 26, 27) . Additionally, C. difficile ST1 appears to be less prevalent than other STs in the natural environment (samples not associated with the human gut or hospital) based upon environmental survey studies (30, 31, 106) . LS-BSR analysis indicated that genomic regions were highly conserved within ST1 genomes, as well as a number of regions that have been broadly deleted within ST1 genomes (Table S12 ). Reduction of the core genome can be associated with niche differentiation (107, 108) . The observed genome region acquisition and loss across ST1 may be associated with its almost exclusive presence in the human/hospital environment. An analysis of other STs demonstrates that the gene gain/loss may be more prevalent in ST1 than other toxigenic clades. However, as most sampling efforts are focused on clinical settings, prevalence of ST1 in other environments is not fully understood. Genetic variability within ST1 may also contribute to the success of the lineage. For instance, resistance to clindamycin is not universal within ST1 (4, 109) but would provide an advantage to some ST1 isolates. Genomics alone cannot definitively identify why ST1 is such a successful lineage of C. difficile, but can identify targets for further investigation (e.g. CDSs identified in Table S12 ).
Additionally, here we focus on bacterial genomics without consideration of factors such as variation in gene regulation, host immune response, or hospital practices such as antimicrobial use policies. For example, with the curtailed use of quinolones in some areas, ST42 (RT106) now appears to be the most dominant C. difficile sequence type in the United States (110) .
C. difficile isolates have been differentiated using a variety of methods including
MLST and PCR ribotyping. In this study, we used the MLST designation, as we can easily genotype sequenced genomes in silico in the absence of ribotyping data.
However, due to recombination, phylogenies inferred from a concatenation of MLST markers have been shown to be incongruent with WGS phylogenies (111) . Using whole genome sequence data for C. difficile, we demonstrate that multiple STs are paraphyletic on the core genome SNP phylogeny (Figure 1 ). This is important if common STs are expected to have a shared evolutionary history, yet the history is conflicting when using the entire genome. Ribotyping represents a legacy method that is still used to type isolates and infer relationships. However, there remains a disconnect between ribotyping and sequencing methods. In this manuscript, we present a workflow that can associate raw sequence data from ST1 genomes to a ribotype profile (RT027). The amplicons that were used for in silico ribotyping were identified from only three complete ST1 genomes; draft genomes are not useful for the identification of predicted amplicons due to the potential collapse of repeat regions (e.g. 16S rRNA genes) (112) . As additional complete genomes are generated from diverse ribotypes, this method can be modified to associate ribotype information with whole genome sequence and MLST data, which is useful for bridging between different methodologies. Whole genome sequencing and analysis provides the highest resolution method for comparing C. difficile isolates and should be included in epidemiological studies if possible.
This study has provided a large-scale analysis into a single sequence type of C.
difficile in order to place isolates from a local healthcare network into a global context and to understand the diversity within a successful, world-wide C. difficile sequence type. The analyses indicated multiple introductions of C. difficile ST1 into the healthcare network, provided insight into potential transmission of C. difficile within the healthcare network, and identified AMR variation among isolates. The genomic diversity within the ST1 genomes suggests that broadly applying labels to ST1 genomes, such as hypervirulent clone, may be inappropriate without an in-depth analysis of the gene presence/absence and SNP markers for antimicrobial resistance.
Additional studies into how genomic variation affects toxin production and virulence are needed to assess the phenotypic diversity of ST1 as it relates to the observed genotypic diversity; these studies are currently ongoing and will help shape how we approach studies using sub-genomic information, such as ribotyping and MLST.
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